Webinar: Is the Pipetting Tip Shortage Putting Your Assay Data at Risk?

WESTBROOK, ME (April 12, 2021) – During COVID, the massive increase in automated testing combined with manufacturing limitations has caused a significant shortage in disposable pipette tips.  As a result, scientists are switching to alternative disposable pipette tip brands, are in some cases reusing tips, or are including tip washing in their daily protocol.  Without properly qualifying these alternate approaches the assays performed with these tips often suffer from poor data quality, lot to lot variability, or sporadic failures.  How can a laboratory address these issues?

The webinar entitled “Evaluating Disposable Pipette Tip Performance: Guided by Science” addresses the attributes that affect pipette tip quality during manufacture and how brands may perform differently and the uncertainties involved with tip reuse, and concludes with advice on how to design and institute an effective tip performance verification program.  This quantitative approach provides you with data allowing you to make informed decisions.  By implementing a verification program to qualify alternative sources of tips or methods of tip use you can ensure that the tips meet your specifications before embarking on large screenings or diagnostic testing campaigns.

Evaluating Disposable Pipette Tip Performance: Guided by Science
Date: Wednesday, April 28, 2021
Time: 2:00pm ET

What you will learn:

  • Factors that affect disposable tip quality
  • How to improve success in automated assay development
  • How to use Artel MVS to quantitatively compare performance of disposable pipette tips

You can sign up for the webinar here.

Nat Hentz, PhdDr. Nathaniel Hentz is currently Director, Scientific Market Development at Artel.  Prior to that, Dr. Hentz served as Assistant Director of the BTEC Analytical Lab at North Carolina State University for almost 11 years.  In that role, he taught both undergraduate and graduate level courses as well as industry short courses focused on biopharmaceutical assay development and validation.  Dr. Hentz’s tenure in the HTS industry includes nearly two years supporting the automated screening systems within the Lead Discovery group at Bristol-Myers Squibb in Connecticut and seven years developing screens at Eli Lilly RTP Laboratories in North Carolina.